Discover how our integrated approach to analysing world Healthcare markets gives you the insight you need to inform critical decisions.


Sun Will Face Uphill Struggle To Return To Growth

Sun Pharmaceutical Industries will face an uphill struggle in its new fiscal year to return to sales growth, and of particular concern will be the net loss recorded in Q118. Issues in both India and the US, the firm's two largest markets, have hampered Sun, but the situation in the US is especially pressing. Revitalising its presence in the US will be essential for Sun to turn its fortunes around; continued declines in Q218 will see US sales halve over their value two years ago.





Kaushal Shah

Head of Pharmaceuticals and Healthcare Research
Pharmaceuticals & Healthcare | London

Jamie Davies

Head of Pharmaceuticals, Medical Devices and Healthcare Research
Pharmaceuticals & Healthcare | London


By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.